Carregant...

Risk Stratification Using Cerebrospinal Fluid Biomarkers in Patients with Mild Cognitive Impairment: An Exploratory Analysis

BACKGROUND: Cerebrospinal fluid (CSF) biomarkers can distinguish Alzheimer’s disease (AD) patients from normal controls; however, their interpretation and potential for use in patients with mild cognitive impairment (MCI) remains unclear. OBJECTIVE: To examine whether biomarker levels allow for risk...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Alzheimers Dis
Autors principals: Michaud, Tzeyu L., Kane, Robert L., McCarten, J. Riley, Gaugler, Joseph E., Nyman, John A., Kuntz, Karen M.
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6342191/
https://ncbi.nlm.nih.gov/pubmed/26401707
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3233/JAD-150066
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!